Tarsus Pharmaceuticals (TARS) Total Non-Current Liabilities (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Total Non-Current Liabilities of $216.1 million for Q1 2026, up 3.83% quarter-over-quarter from $208.1 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $216.1 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $216.1 million; the TTM figure through Mar 2026 stood at $216.1 million (changed N/A YoY), while the FY2025 annual figure was $208.1 million, up 36.52% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $216.1 million, up from $208.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $216.1 million in Q1 2026, with the low at $31.0 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $66.8 million (2023), against an average of $95.2 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 224.45% in 2022, then advanced 18.81% in 2023.
- Tarsus Pharmaceuticals' Total Non-Current Liabilities stood at $34.9 million in 2022, then surged by 91.48% to $66.8 million in 2023, then surged by 128.38% to $152.5 million in 2024, then surged by 36.52% to $208.1 million in 2025, then grew by 3.83% to $216.1 million in 2026.
- Business Quant data shows TARS's Total Non-Current Liabilities at $216.1 million in Q1 2026, $208.1 million in Q4 2025, and $189.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 248.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 248.52 Mn |
| Mar 31, 2026 | 216.11 Mn |
| Dec 31, 2025 | 208.13 Mn |
| Sep 30, 2025 | 189.33 Mn |
| Dec 31, 2024 | 152.46 Mn |
| Sep 30, 2024 | 137.58 Mn |
| Jun 30, 2024 | 123.15 Mn |
| Mar 31, 2024 | 72.46 Mn |
| Dec 31, 2023 | 66.76 Mn |
| Sep 30, 2023 | 52.96 Mn |
| Jun 30, 2023 | 39.37 Mn |
| Mar 31, 2023 | 37.77 Mn |
| Dec 31, 2022 | 34.86 Mn |
| Sep 30, 2022 | 33.63 Mn |
| Jun 30, 2022 | 30.98 Mn |
| Mar 31, 2022 | 31.79 Mn |
| Dec 31, 2021 | 11.48 Mn |
| Sep 30, 2021 | 10.37 Mn |
| Jun 30, 2021 | 10.46 Mn |
| Mar 31, 2021 | 10.12 Mn |